Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Non-Malignant Channel is supported with funding from Agios (Gold).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

EHA 2020 | PEGASUS: pegcetacoplan for PNH

Peter Hillmen • 17 Jun 2020
EHA 2020
Non-Malignant Paroxysmal Nocturnal Hemoglobinuria Antibodies Eculizumab Pegcetacoplan
PEGASUS

Peter Hillmen, MBChB, FRCP, FRCPath, PhD, of the University of Leeds, Leeds, UK, discusses a Phase III study (NCT03500549) evaluating the efficacy and safety of pegcetacoplan, a complement 3 inhibitor, in patients with paroxysmal nocturnal hemoglobinuria (PNH). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Peter Hillmen

Key updates from the interim analysis of the FLAIR trial
1:55
Key updates from the interim analysis of the FLAIR trial
Peter Hillmen • 10 Jun 2022
CLL trial updates from EHA 2022
1:03
CLL trial updates from EHA 2022
Peter Hillmen • 10 Jun 2022
Acalabrutinib vs ibrutinib in previously untreated high-risk CLL
1:19
Acalabrutinib vs ibrutinib in previously untreated high-risk CLL
Peter Hillmen • 10 Jun 2022
The role of MRD in decision-making in CLL
1:40
The role of MRD in decision-making in CLL
Peter Hillmen • 10 Jun 2022

Related Videos

Safety and efficacy of etavopivat in adolescents with SCD: the ongoing HIBISCUS Kids trial
3:10
Safety and efficacy of etavopivat in adolescents with SCD: the ongoing HIBISCUS Kids trial
Peter Hillmen • 8 Dec 2025
A case report used to evaluate gene therapy outcomes in transfusion-dependent β-thalassemia
1:54
A case report used to evaluate gene therapy outcomes in transfusion-dependent β-thalassemia
Peter Hillmen • 2 Dec 2025
Exciting and potentially practice-changing hemophilia updates from ASH 2025
1:59
Exciting and potentially practice-changing hemophilia updates from ASH 2025
Peter Hillmen • 12 Dec 2025
Plasma-derived VWF/FVIII prophylaxis in children under 6 with VWD: first results from WIL-33
2:51
Plasma-derived VWF/FVIII prophylaxis in children under 6 with VWD: first results from WIL-33
Peter Hillmen • 8 Dec 2025
The content of VJHemOnc is intended for healthcare professionals